(Reuters) – Johnson & Johnson said on Monday John Reed will take the role of executive vice president of pharmaceuticals,…
Thousands of J&J talc lawsuits in New Jersey get new judge
By Brendan Pierson (Reuters) – A new judge has been assigned to oversee tens of thousands of lawsuits in New…
Alcon to pay Johnson & Johnson $199 million to settle eye-laser cases
By Blake Brittain (Reuters) – Alcon Vision LLC will pay Johnson & Johnson’s J&J Surgical Vision Inc $199 million to…
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data
By Amruta Khandekar and Bhanvi Satija (Reuters) – Initial public offerings by small private biotech companies are poised to stage…
Martin Shkreli: I’m not in contempt over drug industry ban
By Jonathan Stempel NEW YORK (Reuters) – Martin Shkreli on Friday urged a U.S. judge not to hold him in…
AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
By Leroy Leo and Mariam ESunny (Reuters) – AbbVie Inc said on Thursday it expects sales of its flagship rheumatoid…
Tenet Healthcare’s fourth-quarter beat puts 2023 concerns at bay
(Reuters) -Tenet Healthcare Corp on Thursday beat Wall Street estimates for fourth-quarter results as growth in its outpatient service business…
U.S. investigating Elon Musk’s Neuralink over hazardous pathogens
By Rachael Levy (Reuters) -The U.S. Department of Transportation said on Thursday it is investigating Elon Musk’s brain-implant company Neuralink…
AstraZeneca goes for growth with new drugs as COVID sales wane
By Natalie Grover and Maggie Fick LONDON (Reuters) – AstraZeneca on Thursday said it was poised to grow in 2023…
Centene reaches $215 million settlement addressing California drug overcharges
By Jonathan Stempel (Reuters) – Centene Corp has reached a $215.4 million settlement with California to resolve accusations it overcharged…